Abstract
Influenza remains an important cause of morbidity and mortality, and incurs substantial economic costs (mainly due to hospitalisation) especially for the elderly aged 65 years or more, and among those with high-risk medical conditions. Influenza vaccination is the most effective control measure for both healthy populations and the chronically ill in whom complications of influenza cluster. Unfortunately, vaccination is less effective in the elderly and immunocompromised persons. Additional benefit may accrue from other health care interventions including antiviral therapy. Oseltamivir, a neuraminidase inhibitor, has become a drug of public health importance since it was included in influenza pandemic management plans. Many systematic reviews and meta-analyses of oseltamivir treatment and prophylaxis trials have been published. We provide a summary of the conclusions and review the various findings of economic analyses. Future randomised controlled trials should focus upon costly outcomes such as hospital admissions and should be conducted in populations at high risk of complications from influenza. Future economic analyses need to address variation in (1) willing-to-pay value, (2) annual attack rate of influenza, and (3) influenza vaccination effectiveness and uptake rates.
Keywords: Adolescents, adults, clinical impact, economic review, influenza, oseltamivir.
Infectious Disorders - Drug Targets
Title:Oseltamivir Use in Adolescents and Adults: Clinical and Economic Considerations
Volume: 13 Issue: 1
Author(s): J. Kevin Yin, Leon Heron, Glenn Salkeld, Harunor Rashid and Robert Booy
Affiliation:
Keywords: Adolescents, adults, clinical impact, economic review, influenza, oseltamivir.
Abstract: Influenza remains an important cause of morbidity and mortality, and incurs substantial economic costs (mainly due to hospitalisation) especially for the elderly aged 65 years or more, and among those with high-risk medical conditions. Influenza vaccination is the most effective control measure for both healthy populations and the chronically ill in whom complications of influenza cluster. Unfortunately, vaccination is less effective in the elderly and immunocompromised persons. Additional benefit may accrue from other health care interventions including antiviral therapy. Oseltamivir, a neuraminidase inhibitor, has become a drug of public health importance since it was included in influenza pandemic management plans. Many systematic reviews and meta-analyses of oseltamivir treatment and prophylaxis trials have been published. We provide a summary of the conclusions and review the various findings of economic analyses. Future randomised controlled trials should focus upon costly outcomes such as hospital admissions and should be conducted in populations at high risk of complications from influenza. Future economic analyses need to address variation in (1) willing-to-pay value, (2) annual attack rate of influenza, and (3) influenza vaccination effectiveness and uptake rates.
Export Options
About this article
Cite this article as:
Yin Kevin J., Heron Leon, Salkeld Glenn, Rashid Harunor and Booy Robert, Oseltamivir Use in Adolescents and Adults: Clinical and Economic Considerations, Infectious Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/18715265112129990008
DOI https://dx.doi.org/10.2174/18715265112129990008 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry NF-κB Inhibitors in Head and Neck Cancer
Letters in Drug Design & Discovery Radionuclide Imaging in Drug Development
Current Pharmaceutical Design Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma
Current Pharmaceutical Biotechnology S1P Regulation of Macrophage Functions in the Context of Cancer
Anti-Cancer Agents in Medicinal Chemistry Genetic Engineering in Allotransplantation of Vascularized Organs
Current Gene Therapy New Developments in the Diagnosis and Management of Resistant Hypertension
Current Medicinal Chemistry FMRI of the Emotions: Towards an Improved Understanding of Amygdala Function
Current Medical Imaging Trends of Mortalities and Morbidities due to COVID-19, from Explosiveness to Aggressiveness, Gaps in System Response, and Transmission Chain
New Emirates Medical Journal Plasticity and Therapeutic Potential of Mesenchymal Stem Cells in the Nervous System
Current Pharmaceutical Design Hyperpolarized <sup>13</sup>C MR Angiography
Current Pharmaceutical Design Exhaled Breath Biomonitoring Using Laser Spectroscopy
Current Analytical Chemistry The Processing of Chitosan and Its Derivatives and Their Application for Postoperative Anti-Adhesion
Mini-Reviews in Medicinal Chemistry FTY720: A Most Promising Immunosuppressant Modulating Immune Cell Functions
Mini-Reviews in Medicinal Chemistry Applications of FDG-PET/CT in Assessment of Vascular Infection and Inflammation
Current Molecular Imaging (Discontinued) Venous Collateral Circulation of the Extracranial Cerebrospinal Outflow Routes
Current Neurovascular Research Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Diffuse Large B-Cell Lymphoma Presenting as an Anterior Chest Wall Mass: A Case Report and Literature Review
Current Respiratory Medicine Reviews Case Report of a Large Rhinolith Cast – A Frequently Missed Diagnosis
New Emirates Medical Journal Crofelemer: In HIV Associated Diarrhea and Secretory Diarrhea - A Patent Perspective
Recent Patents on Anti-Infective Drug Discovery